Clinical trials: Anger
Cardiovascular Diseases, Mood Disorders
Evaluating the Effects of Omega-3 Fatty Acids on Heart Disease and Behavior
Omega-3 fatty acids are a certain kind of fish fat that has recently been shown to have health benefits. This study will examine the effectiveness of fish oil supplementation for reducing the early signs of heart disease risk and…
- Conditions
- Cardiovascular Diseases, Mood Disorders, Inflammation
- Trial name
- NCT00663871
- Testing
- Fish Oil
- Where
- United States
- Volunteers
- 272 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Part I (SAD) - Healthy Participants, Part II (MAD) - Chronic Obstructive Pulmonary Disease
Safety and Tolerability of MEDI3506 in Healthy Participants, in Participants With COPD and Healthy Japanese Participants
This is a Phase 1, randomised, blinded, placebo controlled, study designed to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity response to single and multiple doses of MEDI3506.
- Conditions
- Part I (SAD) - Healthy Participants, Part II (MAD) - Chronic Obstructive Pulmonary Disease, Part III (J-SD) - Healthy Japanese Participants
- Trial name
- NCT03096795
- Testing
- MEDI3506
- Where
- 2 sites in United Kingdom
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Healthy Elderly, Parkinson Disease
A Study to Assess Single and Multiple Doses of IkT-148009 in Healthy Elderly Participants and Parkinson's Patients
This study investigates the safety and tolerability of drug IkT-148009 in healthy elderly volunteers (55 to 70 years old). This first-in-human study is designed in 3 parts.
- Trial name
- NCT04350177
- Testing
- IkT-148009
- Where
- 4 sites in United States
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- ABLi Therapeutics, Inc.
Bacterial Infections
P1 Single and Multiple Ascending Dose (SAD/MAD) Study of IV QPX7728 Alone and Combined With QPX2014 in NHV
QPX7728 is an ultra-broad-spectrum beta-lactamase inhibitor, with activity against numerous beta-lactamases, including class A extended spectrum beta-lactamases (ESBLs), class C cephalosporinases, and extended spectrum class D…
- Trial name
- NCT04380207
- Testing
- QPX7728, QPX2014
- Where
- 2 sites in United States, Australia
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Qpex Biopharma, Inc.
Healthy
Study of Safety, Tolerability and PK, PD of HPG1860 in Healthy Subjects
This is a randomized, double-blind, placebo-controlled, single and multiple ascending dose Phase 1study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of HPG1860 orally administered in…
- Trial name
- NCT04480697
- Testing
- HPG1860
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Hepagene (Shanghai) Co., Ltd.
Healthy Volunteers
SAD and MAD Study With IV and SC Doses of ARGX-117
This is a phase 1, first-in-human, double-blinded, randomized, placebo-controlled, escalating single and multiple dose levels trial to evaluate the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of ARGX-117…
- Trial name
- ARGX-117 (NCT04532125)
- Testing
- ARGX-117, ARGX-117 + rHuPH20, ARGX-117 PH20 SC
- Where
- Netherlands
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- argenx
Healthy Volunteers
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers
The goal of this clinical trial was to learn about the safety and tolerability of an investigational drug called Benfo-oxythiamine (B-OT) in healthy male volunteers.
- Trial name
- BOOST (NCT07450833)
- Testing
- Benfo-oxythiamine
- Where
- Bulgaria
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Benfovir AG
Healthy
A Study of HNC042 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics.
The purpose of this First-in-Human study is to evaluate the safety , tolerability and pharmacokinetics after single ascending of HNC042 given to healthy subjects, compared to placebo.
- Trial name
- NCT03740555
- Testing
- HNC042 single dose, HNC042 multiple ascending doses
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Guangzhou Henovcom Bioscience Co. Ltd.
Healthy
AZD7325 Japan Multiple Ascending Dose (MAD) Study
The purpose of this study is to evaluate the safety and tolerability after repeated ascending doses of AZD7325 in Japanese healthy male subjects.
- Trial name
- JMAD (NCT00945425)
- Testing
- AZD7325
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
The Safety, Tolerability, PK, and PD of DWP213388 After SAD and MAD Administration in Healthy Adult Subjects
A Phase 1, First-in-human, Randomized, Double-blind, Placebo controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DWP213388 after Single and Multiple Ascending Oral Dose Administration in…
- Trial name
- NCT05607589
- Testing
- DWP213388
- Volunteers
- healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Healthy Subjects
Study of Orally Administered BEBT-503 in Healthy Subjects
This is a Phase I, randomized, double-blind, placebo-controlled, first-in-human study in which the safety, tolerability, and pharmacokinetic of orally administered BEBT-503 will be assessed in healthy adult subjects.
- Trial name
- NCT05391880
- Testing
- BEBT-503 20mg, BEBT-503 40mg, BEBT-503 80mg
- Where
- Australia
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- BeBetter Med Inc
Allergic Bronchopulmonary Aspergillosis
Phase 1 Three Part SAD, MAD & Cross-Over Study of ZP-059 in Healthy and Asthmatic Subjects
The primary safety objectives were: Part 1: To determine the safety and tolerability of single doses of ZP-059 in healthy subjects Part 2: To determine the safety and tolerability of multiple doses of ZP-059 in subjects with mild…
- Trial name
- NCT04229303
- Testing
- Voriconazole inhaled, oral voriconazole
- Where
- United Kingdom
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Zambon SpA
Parkinson's Disease (PD), Mild to Moderate Parkinson's Disease
A Phase I Study in Healthy Volunteers and Parkinson's Disease (PD) Patients.
The goal of this trial is to learn if MTX325 can be developed as a potential disease-modifying treatment for Parkinson's Disease. Parts 1-4 complete, Part 5 (multiple doses in patients with Parkinson's Disease) in progress.
- Conditions
- Parkinson's Disease (PD), Mild to Moderate Parkinson's Disease, Early Stage Parkinson's Disease
- Trial name
- NCT07630545
- Testing
- MTX325
- Where
- 18 sites in Australia, France and 2 more
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Mission Therapeutics
Healthy
A First-in-Human SAD/MAD Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ENC1018 in Healthy Adult Subjects
This is a Phase 1, FIH, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and PK characteristics of ENC1018 after single and multiple oral dose administration in healthy adult subjects.
- Trial name
- NCT06224400
- Testing
- ENC1018 for SAD, ENC1018 for MAD
- Where
- Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- EnnovaBio Australia Pharmaceuticals Pty Ltd
Chronic Hypoparathyroidism
AZP-3601 SAD and MAD Study in Healthy Subjects and Patients With Hypoparathyroidism
This study is investigating the safety, tolerability, pharmacodynamics and pharmacokinetics of AZP-3601 following single and repeated administration in both healthy volunteers and patients with chronic hypoparathyroidism (cHP)…
- Trial name
- NCT05239221
- Testing
- AZP-3601
- Where
- 2 sites in Hungary, Netherlands
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Alexion Pharmaceuticals, Inc.
Healthy Volunteers
A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986521 in Healthy Participants.
The purpose of this study is to evaluate the safety, tolerability, and drug levels of BMS-986521 following single and multiple ascending doses of BMS-986521 in healthy adult participants, and to evaluate potential food effects on…
- Trial name
- NCT07283263
- Testing
- BMS-985521
- Where
- United States
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Healthy
Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Multiple Ascending Doses of CM3.1-AC100 in Healthy Male Volunteers
The primary objective is to assess the safety and tolerability of the GLP-1 peptide analogue CM3.1-AC100 after repeated subcutaneous (sc) doses.
- Trial name
- NCT01165502
- Testing
- CM3.1-AC100
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- CellMed AG, a subsidiary of BTG plc.
Cystic Fibrosis
SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects
This is a Phase 1/2a randomized, double-blind, two-part, dose-ascending, multicenter study of AR-501 (gallium citrate) solution, administered via inhalation, in healthy adult and P.
- Trial name
- NCT03669614
- Testing
- Inhaled AR-501
- Where
- 25 sites in United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Aridis Pharmaceuticals, Inc.
Bacterial Infections
SAD/MAD Safety and PK Study of QPX9003 (Novel Polymyxin) in Normal Healthy Volunteers
The worldwide spread of resistance to antibiotics among gram-negative bacteria, particularly members of the ESKAPE group of pathogens, has resulted in a crisis in the treatment of hospital acquired infections.
- Trial name
- QPX9003 (NCT04808414)
- Testing
- QPX9003 for IV Infusion
- Where
- United States
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Qpex Biopharma, Inc.
Healthy
A Study of Single and Multiple Ascending Doses of TC-5214 in Japanese Healthy Elderly Male and Female Volunteers
The purpose of this study is to assess safety, tolerability and pharmacokinetics of TC-5214 in elderly healthy Japanese volunteers.
- Trial name
- NCT01392820
- Testing
- TC-5214
- Where
- Japan
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AstraZeneca